keyword
MENU ▼
Read by QxMD icon Read
search

arm transplant

keyword
https://www.readbyqxmd.com/read/28533058/music-therapy-for-symptom-management-after-autologous-stem-cell-transplantation-results-from-a-randomized-study
#1
Debbie Bates, Brian Bolwell, Navneet S Majhail, Lisa Rybicki, Melissa Yurch, Donna Abounader, Joseph Kohuth, Shannon Jarancik, Heather Koniarczyk, Linda McLellan, Jane Dabney, Christine Lawrence, Lisa Gallagher, Matt Kalaycio, Ronald Sobecks, Robert Dean, Brian Hill, Brad Pohlman, Betty K Hamilton, Aaron T Gerds, Deepa Jagadeesh, Hien D Liu
High-dose chemotherapy followed by autologous stem cell transplant (ASCT) is frequently performed in patients with hematologic malignancies. ASCT can result in significant nausea, pain, and discomfort. Supportive care has improved and pharmacologic therapies are frequently employed, but with limitations. Music has been demonstrated to improve nausea and pain in patients undergoing chemotherapy but few data are available regarding the effects of music therapy in the transplant setting. In a prospective study, patients with lymphoma or multiple myeloma undergoing ASCT were randomized to receive either interactive music therapy (MT) with a board-certified music therapist or no music therapy (No MT)...
May 19, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28517112/patterns-and-correlates-of-adherence-to-self-monitoring-in-lung-transplant-recipients-during-the-first-12-months-after-discharge-from-transplant
#2
Lu Hu, Annette DeVito Dabbs, Mary Amanda Dew, Susan M Sereika, Jennifer H Lingler
Self-monitoring of lung function, vital signs, and symptoms is crucial for lung transplant recipients (LTRs) to ensure early detection of complications and prompt intervention. This study sought to identify patterns and correlates of adherence to self-monitoring among LTRs over the first 12-months post-discharge from transplant. This study analyzed existing data from the usual care arm participants of a randomized clinical trial who tracked self-monitoring activities using paper-and-pencil logs. Adherence was calculated as the percent of days LTRs recorded any self-monitoring data per interval: hospital discharge-2 months, 3-6 months, and 7-12 months...
May 18, 2017: Clinical Transplantation
https://www.readbyqxmd.com/read/28511545/fosfomycin-tromethamine-for-the-treatment-of-cystitis-in-abdominal-solid-organ-transplant-recipients-with-renal-dysfunction
#3
Luiza Kerstenetzky, Margaret R Jorgenson, Jillian L Descourouez, Glen Leverson, Warren E Rose, Robert R Redfield, Jeannina A Smith
BACKGROUND: Urinary tract infection (UTI) after abdominal solid organ transplantation (SOT) is associated with significant morbidity and mortality. Fosfomycin tromethamine (FOS), a uroselective antibiotic, is FDA approved for uncomplicated UTIs in women and is used off-label for complicated UTIs and prostatitis in men. Literature supporting the use of FOS in the SOT population is limited, and efficacy is questioned in the setting of renal dysfunction. OBJECTIVE: To evaluate the success of FOS for the treatment of cystitis in SOT patients with renal dysfunction...
May 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28506905/eight-millimeter-covered-tips-does-not-compromise-shunt-function-but-reduces-hepatic-encephalopathy-in-preventing-variceal-rebleeding
#4
Qiuhe Wang, Yong Lv, Ming Bai, Zhengyu Wang, Haibo Liu, Chuangye He, Jing Niu, Wengang Guo, Bohan Luo, Zhanxin Yin, Wei Bai, Hui Chen, Enxin Wang, Dongdong Xia, Xiaomei Li, Jie Yuan, Na Han, Hongwei Cai, Tao Li, Huahong Xie, Jielai Xia, Jianhong Wang, Hongbo Zhang, Kaichun Wu, Daiming Fan, Guohong Han
BACKGROUND AND AIMS: Currently, there are no recommendations in guidelines concerning the preferred diameter of stents for transjugular intrahepatic portosystemic shunt (TIPS) owing to the lack of adequate evidence. We therefore evaluated that compared with 10-mm stents, whether 8-mm stents would achieve similar shunt function with less hepatic encephalopathy (HE) and better liver function. METHODS: Cirrhotic patients were randomly assigned to receive TIPS with an 8-mm or 10-mm covered stent to prevent variceal rebleeding...
May 12, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28504892/palliative-care-interventions-before-left-ventricular-assist-device-implantation-in-both-bridge-to-transplant-and-destination-therapy
#5
Shunichi Nakagawa, Melana Yuzefpolskaya, Paolo C Colombo, Yoshifumi Naka, Craig D Blinderman
BACKGROUND: The optimal level of palliative care (PC) involvement in left ventricular assist device (LVAD) therapy has yet to be determined. OBJECTIVE: Describe the feasibility of PC intervention to elucidate patients' goals and values in LVAD therapy in both destination therapy (DT) and bridge to transplant (BTT). DESIGN: Single center, prospective, single-arm study. SETTING/SUBJECTS: All patients who received mandatory PC consultation, using a semistructured script, before LVAD implantation (PreVAD evaluation)...
May 15, 2017: Journal of Palliative Medicine
https://www.readbyqxmd.com/read/28485360/monotherapy-versus-combination-therapy-against-carbapenem-resistant-gram-negative-bacteria-a-retrospective-observational-study
#6
A Ghafur, V Devarajan, T Raja, J Easow, M A Raja, S Sreenivas, B Ramakrishnan, S G Raman, D Devaprasad, B Venkatachalam, R Nimmagadda
BACKGROUND: Colistin-based combination therapy (CCT) is extensively used to treat infections due to carbapenem-resistant Gram-negative bacteria (CRGNB). There are no data available from India on the usefulness of combination therapy, especially in the oncology setup. The aim of this study was to analyze the clinical effectiveness of CCT over monotherapy in patients with CRGNB. MATERIALS AND METHODS: We conducted a retrospective, observational study of patients with CRGNB bloodstream infections in our oncology and bone marrow transplant center...
October 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28485023/a-randomized-phase-ii-study-of-standard-dose-versus-high-dose-rituximab-with-beam-in-autologous-stem-cell-transplantation-for-relapsed-aggressive-b-cell-non-hodgkin-lymphomas-long-term-results
#7
Samer A Srour, Shaoying Li, Uday R Popat, Muzaffar H Qazilbash, Sara Lozano-Cerrada, Farzeneh Maadani, Amin Alousi, Partow Kebriaei, Paolo Anderlini, Yago Nieto, Roy Jones, Elizabeth Shpall, Richard E Champlin, Chitra Hosing
High-dose rituximab (HD-R) combined with carmustine, cytarabine, etoposide and melphalan (BEAM) and autologous stem cell transplant (ASCT) was effective and tolerable in a single-arm prospective study of relapsed aggressive B-cell non-Hodgkin lymphoma (R-NHL). We performed a randomized phase 2 study comparing HD-R versus standard-dose rituximab (SD-R) in R-NHL. Ninety-three patients were randomized to HD-R (1000 mg/m(2) ) (n = 42) or SD-R (375 mg/m(2) ) (n = 51) administered on post-transplant days +1 and +8, using a Bayesian adaptive algorithm...
May 9, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28483983/efficacy-of-interventions-for-adherence-to-the-immunosuppressive-therapy-in-kidney-transplant-recipients-a-meta-analysis-and-systematic-review
#8
Yichen Zhu, Yifan Zhou, Lei Zhang, Jian Zhang, Jun Lin
Immunosuppressive treatment regimens are complex and require ongoing self-management. Medication adherence can be difficult to achieve for several reasons. The current meta-analysis and systematic review investigated whether adherence interventions improved immunosuppressive treatment adherence in kidney transplant recipients. Medline, Cochrane, EMBASE, and Google Scholar were searched until October 17, 2016 using the following search terms: kidney transplantation, compliance, adherence, and immunosuppressive therapy...
May 8, 2017: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
https://www.readbyqxmd.com/read/28466536/a-retrospective-analysis-of-3954-patients-in-phase-2-3-trials-of-bortezomib-for-the-treatment-of-multiple-myeloma-towards-providing-a-benchmark-for-the-cardiac-safety-profile-of-proteasome-inhibition-in-multiple-myeloma
#9
Jacob P Laubach, Javid J Moslehi, Sanjeev A Francis, Jesús F San Miguel, Pieter Sonneveld, Robert Z Orlowski, Philippe Moreau, Laura Rosiñol, Edward A Faber, Peter Voorhees, Maria-Victoria Mateos, Loreta Marquez, Huaibao Feng, Avinash Desai, Helgi van de Velde, Jennifer Elliott, Hongliang Shi, Edward Dow, Nishith Jobanputra, Dixie-Lee Esseltine, Liviu Niculescu, Kenneth C Anderson, Sagar Lonial, Paul G Richardson
This retrospective analysis aimed to establish the overall cardiac safety profile of bortezomib using patient-level data from one phase 2 and seven phase 3 studies in previously untreated and relapsed/refractory multiple myeloma (MM). Seven clinically relevant primary [congestive heart failure (CHF), arrhythmias, ischaemic heart disease (IHD), cardiac death] and secondary (hypertension, dyspnoea, oedema) cardiac endpoints were defined based on MedDRA v16.0 preferred terms. 2509 bortezomib-treated patients and 1445 patients in non-bortezomib-based control arms were included...
May 3, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28455005/outcomes-of-allogeneic-hematopoietic-cell-transplantation-in-acute-myeloid-leukemia-patients-with-abnormalities-of-the-short-arm-of-chromosome-17
#10
Jinichi Mori, Masamitsu Yanada, Naoyuki Uchida, Takahiro Fukuda, Toru Sakura, Michihiro Hidaka, Kyoko Watakabe-Inamoto, Heiwa Kanamori, Hiroyasu Ogawa, Tatsuo Ichinohe, Junji Tanaka, Yoshiko Atsuta, Shingo Yano
We retrospectively analyzed a Japanese nationwide database to elucidate the impact of abnormalities in the short arm of chromosome 17 (abnl[17p]) on the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia. Of 10,923 patients, 262 (2.4%) had abnl(17p), 235 of whom were classified into the poor cytogenetic risk group according to the National Comprehensive Cancer Network criteria. The median follow-up period was 1425 days. In abnl(17p) versus non-abnl(17p) patients of poor cytogenetic risk group, overall survival (OS), disease-free survival, cumulative incidence of disease relapse, and nonrelapse mortality rates at 5 years after allo-HSCT were 9...
April 25, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28441111/phase-ii-study-of-the-efficacy-and-safety-of-pembrolizumab-for-relapsed-refractory-classic-hodgkin-lymphoma
#11
Robert Chen, Pier Luigi Zinzani, Michelle A Fanale, Philippe Armand, Nathalie A Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A Shipp, Yinghua Zhang, Alejandro D Ricart, Arun Balakumaran, Craig H Moskowitz
Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1-blocking antibody, demonstrated a high overall response rate (ORR) in patients with relapsed or refractory classic Hodgkin lymphoma (rrHL) in phase I testing. Methods KEYNOTE-087 ( ClinicalTrials.gov identifier, NCT02453594) was a single-arm phase II study of pembrolizumab in three cohorts of patients with rrHL, defined on the basis of lymphoma progression after (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV); (2) salvage chemotherapy and BV, and thus, ineligible for ASCT because of chemoresistant disease; and (3) ASCT, but without BV after transplantation...
April 25, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28438889/fda-approval-summary-nivolumab-for-the-treatment-of-relapsed-or-progressive-classical-hodgkin-lymphoma
#12
Yvette L Kasamon, R Angelo de Claro, Yaping Wang, Yuan Li Shen, Ann T Farrell, Richard Pazdur
On May 17, 2016, after an expedited priority review, the U.S. Food and Drug Administration granted accelerated approval to nivolumab for the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin (BV). Nivolumab in cHL had been granted breakthrough therapy designation. Accelerated approval was based on two single-arm, multicenter trials in adults with cHL. In 95 patients with relapsed or progressive cHL after autologous HSCT and post-transplantation BV, nivolumab, dosed at 3 mg/kg intravenously every 2 weeks, produced a 65% (95% confidence interval: 55%-75%) objective response rate (58% partial remission, 7% complete remission)...
May 2017: Oncologist
https://www.readbyqxmd.com/read/28433740/xenotransplantation-of-layer-by-layer-encapsulated-non-human-primate-islets-with-a-specified-immunosuppressive-drug-protocol
#13
Muhammad R Haque, Jiwoong Kim, Hyojun Park, Han Sin Lee, Kyo Won Lee, Taslim A Al-Hilal, Jee-Heon Jeong, Cheol-Hee Ahn, Doo Sung Lee, Sung Joo Kim, Youngro Byun
Islet transplantation is as effective as but also less immunogenic than pancreas transplantation for the treatment of type 1 diabetes mellitus. However, as the complete elimination of immunogenicity still remains a major obstacle in islet transplantation, layer-by-layer encapsulation (LbL) of pancreatic islets using biocompatible polymers offers a rational approach to reducing host immune response towards transplanted islets. We investigated the effect of LbL of non-human primate (NHP) islets on reducing immunogenicity as a preclinical model since NHPs have close phylogenetic and immunological relationship with humans...
April 19, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28429876/iodine-131-meta-iodobenzylguanidine-therapy-for-patients-with-newly-diagnosed-high-risk-neuroblastoma
#14
REVIEW
Kathelijne Cjm Kraal, Elvira C van Dalen, Godelieve Am Tytgat, Berthe Lf Van Eck-Smit
BACKGROUND: Patients with newly diagnosed high-risk (HR) neuroblastoma (NBL) still have a poor outcome, despite multi-modality intensive therapy. This poor outcome necessitates the search for new therapies, such as treatment with (131)I-meta-iodobenzylguanidine ((131)I-MIBG). OBJECTIVES: To assess the efficacy and adverse effects of (131)I-MIBG therapy in patients with newly diagnosed HR NBL. SEARCH METHODS: We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL; the Cochrane Library 2016, Issue 3), MEDLINE (PubMed) (1945 to 25 April 2016) and Embase (Ovid) (1980 to 25 April 2016)...
April 21, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28417463/pharmacological-interventions-for-primary-sclerosing-cholangitis-an-attempted-network-meta-analysis
#15
REVIEW
Francesca Saffioti, Kurinchi Selvan Gurusamy, Neil Hawkins, Clare D Toon, Emmanuel Tsochatzis, Brian R Davidson, Douglas Thorburn
BACKGROUND: Primary sclerosing cholangitis is a chronic cholestatic liver disease that is associated with both hepatobiliary and colorectal malignancies, which can result in liver cirrhosis and its complications. The optimal pharmacological treatment for patients with primary sclerosing cholangitis remains controversial. OBJECTIVES: To assess the comparative benefits and harms of different pharmacological interventions in people with primary sclerosing cholangitis by performing a network meta-analysis, and to generate rankings of available pharmacological interventions according to their safety and efficacy...
March 28, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28408615/phase-ii-study-of-bortezomib-in-combination-with-cyclophosphamide-and-rituximab-for-relapsed-or-refractory-mantle-cell-lymphoma
#16
Hun Ju Lee, Jorge E Romaguera, Lei Feng, Aakash P Desai, Liang Zhang, Michelle Fanale, Felipe Samaniego, Fredrick B Hagemeister, Luis E Fayad, Maria A Rodriguez, Jeffrey L Medeiros, Kimberly Hartig, Krystle Nomie, Makhdum Ahmed, Maria Badillo, Haige Ye, Yasuhiro Oki, Pei Lin, Loretta Nastoupil, Jason Westin, Michael Wang
BACKGROUND: Relapsed or refractory mantle cell lymphoma (MCL) has a poor prognosis. The best outcome is achieved in patients who have a partial or complete response to salvage treatment and proceed to allogeneic stem cell transplant. PATIENTS AND METHODS: Twenty-one patients were given a combination regimen of bortezomib, cyclophosphamide, and rituximab at MD Anderson Cancer Center as part of a single-arm, prospective, open-label phase II clinical trial. The median age was 66 years, with a median number of prior treatments of three...
May 2017: Oncologist
https://www.readbyqxmd.com/read/28407197/autologous-hematopoietic-stem-cell-transplantation-following-high-dose-chemotherapy-for-nonrhabdomyosarcoma-soft-tissue-sarcomas
#17
REVIEW
Frank Peinemann, Heike Enk, Lesley A Smith
BACKGROUND: Soft tissue sarcomas (STS) are a highly heterogeneous group of rare malignant solid tumors. Nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) comprise all STS except rhabdomyosarcoma. In people with advanced local or metastatic disease, autologous hematopoietic stem cell transplantation (HSCT) applied after high-dose chemotherapy (HDCT) is a planned rescue therapy for HDCT-related severe hematologic toxicity. The rationale for this update is to determine whether any randomized controlled trials (RCTs) have been conducted and to clarify whether HDCT followed by autologous HSCT has a survival advantage...
April 13, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28397548/pre-natal-diagnosis-of-thalassaemia-in-sri-lanka-a-ten-year-review
#18
Kalinga Khemal Nanayakkara, Undugodage Ganganath Rodrigo, Kuda Liyanage Nandika Perera, Chinthani Deepthi Nanayakkara
Thalassaemia is the commonest monogenic disease in Sri Lanka, affecting over 3500 children and half-a-million thalassaemia carriers. This is a review of 82 amniocenteses performed from 2006 to 2016, in the largest prenatal diagnoses study for thalassaemia carried out in Sri Lanka. Amniocenteses were performed between 11 and 12 weeks of ultrasonically confirmed gestation, on mothers with previous thalassaemia major children pregnant for the second time and nulliparous thalassaemia trait women married to trait partners...
April 11, 2017: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28396108/augmented-nurse-care-management-in-ckd-stages-4-to-5-a%C3%A2-randomized-trial
#19
Steven Fishbane, Sofia Agoritsas, Alessandro Bellucci, Candice Halinski, Hitesh H Shah, Vipul Sakhiya, Leah Balsam
BACKGROUND: Outcomes for patients with late-stage chronic kidney disease (CKD) in the United States are suboptimal. There is poor education and preparation for end-stage kidney disease, as well as a high rate of hospitalization in this group of patients. STUDY DESIGN: A randomized, parallel-group, 2-arm, controlled trial. SETTING & PARTICIPANTS: The study was conducted at 3 sites: a clinic of an academic medical center, a public hospital academic clinic, and a community-based private practice...
April 7, 2017: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/28390845/prevalence-of-malnutrition-in-adult-patients-previously-treated-with%C3%A2-allogeneic-hematopoietic-stem-cell-transplantation
#20
Thibault Brotelle, Richard Lemal, Aurélie Cabrespine, Cécile Combal, Eric Hermet, Aurélie Ravinet, Jacques-Olivier Bay, Corinne Bouteloup
INTRODUCTION: Malnutrition is common after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and is a well-known prognostic factor for survival. The nutritional status of patients in a long term after allo-HSCT is less well documented. The main objective of this study was to evaluate the prevalence of malnutrition in adult patients who underwent allo-HSCT more than one year ago. Secondary objectives were to assess body composition, muscle strength, and factors associated with malnutrition...
March 28, 2017: Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition
keyword
keyword
93165
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"